EU releases a proposal to overhaul how pharma does business; Kaiser Permanente to acquire Geisinger in blockbuster deal

Taking stock of the drug industry, from the lab to the medicine chest

April 26, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Sean Gallup/Getty Images STAT+ | EU releases proposed pharma overhaul, cutting period of market exclusivity The legislation, the first major update to the EU's pharma policy in two decades, is sure to face challenges from the drug industry. By Andrew Joseph STAT+ | Kaiser Permanente to acquire Geisinger in blockbuster deal Kaiser Permanente and Geisinger want to combine into a not-for-profit system encompassing health insurance, hospitals, and medical groups. By Bob Herman STAT+ | Another powerful congressional committee is ready to take on PBMs House Oversight will hold a hearing on the results of an investigation into the business practices of drug middlemen known as PBMs. By John Wilkerson Kate Collins/The Journal via AP STAT+ | Early findings in gene therapy death suggest CRISPR was not the cause The death of a muscular dystrophy patient had raised concerns about the promise of using CRISPR-Cas9 to treat many diseases. By Jason Mast STAT+ | Alnylam's 'upstream' Alzheimer's treatment shows early promise Alnylam's treatment is designed to silence the gene responsible for the production of toxic brain plaques thought to drive the disease. By Damian Garde

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser